Endoscopic, Histologic, and Composite Endpoints in Patients with Ulcerative Colitis Treated with Etrasimod [106/120 characters, including spaces].

Fiche publication

Date publication

juillet 2024

Journal

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association

Auteurs

Membres identifiés du Cancéropôle Est :
Pr PEYRIN-BIROULET Laurent

Tous les auteurs :
Magro F, Peyrin-Biroulet L, Sands BE, Danese S, Jairath V, Goetsch M, Bhattacharjee A, Wu J, Branquinho D, Modesto I, Feagan BG

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/39089519

Résumé

Histologic remission, a potentially important treatment target in ulcerative colitis (UC), is associated with favorable long-term outcomes. Etrasimod is an oral, once-daily, selective sphingosine 1-phosphate (S1P) receptor modulator for the treatment of moderately to severely active UC. This post-hoc analysis of the ELEVATE UC program evaluated the efficacy of etrasimod according to histologic and composite (histologic/endoscopic/symptomatic) endpoints and examined their prognostic value.